Natera

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Natera 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NTRA

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). 

CEO
Stephen Leonard Chapman
CEOStephen Leonard Chapman
Employees
6,140
Employees6,140
Headquarters
Austin, Texas
HeadquartersAustin, Texas
Founded
2003
Founded2003
Employees
6,140
Employees6,140

NTRA Key Statistics

Market cap
59.70B
Market cap59.70B
Price-Earnings ratio
-302.72
Price-Earnings ratio-302.72
Dividend yield
—
Dividend yield—
Average volume
1.48M
Average volume1.48M
High today
$431.26
High today$431.26
Low today
$408.32
Low today$408.32
Open price
$425.55
Open price$425.55
Volume
2.36M
Volume2.36M
52 Week high
$437.41
52 Week high$437.41
52 Week low
$181.00
52 Week low$181.00

Stock Snapshot

The current Natera(NTRA) stock price is $414.30, with a market capitalization of 59.7B. The stock trades at a price-to-earnings (P/E) ratio of -302.72.

On 2026-11-01, Natera(NTRA) stock traded between a low of $408.32 and a high of $431.26. Shares are currently priced at $414.30, which is +1.5% above the low and -3.9% below the high.

Natera(NTRA) shares are trading with a volume of 2.36M, against a daily average of 1.48M.

During the past year, Natera(NTRA) stock moved between $181.00 at its lowest and $437.41 at its peak.

During the past year, Natera(NTRA) stock moved between $181.00 at its lowest and $437.41 at its peak.

NTRA News

Simply Wall St 1d
How ESMO Cancer Test Data Will Impact Natera Stock - Simply Wall St

...

How ESMO Cancer Test Data Will Impact Natera Stock - Simply Wall St
Benzinga 2d
Natera, Shake Shack, eBay And More On CNBC’s ‘Final Trades’

On CNBC’s “Halftime Report Final Trades,” Rob Sechan, founder and managing partner of NewEdge Capital Group, picked eBay Inc. (NASDAQ:EBAY). Supporting his vie...

Natera, Shake Shack, eBay And More On CNBC’s ‘Final Trades’
Simply Wall St 4d
Natera Stock May Be 32% Undervalued After ESMO Data

has delivered a very large 3 year share price gain, so the obvious question is whether the current valuation is still grounded in the cash flows the business ca...

Analyst ratings

88%

of 25 ratings
Buy
88%
Hold
8%
Sell
4%

More NTRA News

Simply Wall St 6d
Natera Partners In Colorectal Cancer, Is The Stock Fully Valued?

Advertisement Why this new colorectal cancer alliance matters for Natera stock Natera (NTRA) just announced a colorectal cancer collaboration with TransCode T...

The Motley Fool 6d
Stanley Druckenmiller Has Bet Big on This 1 Healthcare Stock. Here's Why I Disagree.

It can pay to follow the investing legends. That is why investors take a good, hard look at the portfolio of Stanley Druckenmiller, a hedge fund legend who has...

Stanley Druckenmiller Has Bet Big on This 1 Healthcare Stock. Here's Why I Disagree.

People also own

Based on the portfolios of people who own NTRA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.